{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-25-000133","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.337565+00:00","generated_at":"2026-05-17T14:52:05.004252+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025","bullets":["Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.","Cash, cash equivalents and investments totaled $404.1M as of June 30, 2025, expected to fund into mid-2027.","ORX750 Phase 2a CRYSTAL-1 study ongoing; data in NT1, NT2, and idiopathic hypersomnia expected in 2025.","ORX142 Phase 1 first-in-human trial initiated; data in sleep-deprived healthy volunteers expected in 2025.","ORX489 in IND-enabling studies for neuropsychiatric disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-25-000133","json":"https://secwatch.observer/filing/0001847903-25-000133.json","markdown":"https://secwatch.observer/filing/0001847903-25-000133.md","text":"https://secwatch.observer/filing/0001847903-25-000133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000133/0001847903-25-000133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000133/cnta-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:52:05.004252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}